Combination of tacrolimus and mycophenolate mofetil in persistent proteinuria due to refractory childhood lupus nephritis

Abdulaziz Almutairi, Ziyad Alkathiri, Sulaiman M. Al-Mayouf

Pediatric Rheumatology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

Abstract

Background: Children with lupus nephritis particularly, diffuse proliferative and membranous glomerulonephritis, may necessitate potent immunosuppressive medications and occasionally combined therapy.

Objective: To report the beneficial effects of tacrolimus (TAC) in children with refractory lupus nephritis from a single tertiary pediatric rheumatology clinic.

Methods: This is a retrospective case series of children with refractory lupus nephritis treated with TAC after failure of aggressive immunosuppressive treatment. All patients were evaluated at the time of initiation of TAC and at last follow-up visit by assessing the following response parameters: cSLE Disease Activity Index (SLEDAI), urine protein/creatinine ratio, urine sediments, serum albumin, complement (C3 and C4), anti-double-stranded DNA (dsDNA) antibody levels, and renal function assessed by glomerular filtration rate (eGFR).

Results: Three children (two girls and one boy) with lupus nephritis and persistent nephrotic-range proteinuria failed prednisone treatment as well as sequential treatment of cyclophosphamide, mycophenolate mofetil (MMF), and rituximab. When TAC was administered along with MMF and prednisone, all patients showed improvement in response parameters, namely, SLEDAI, serum albumin, and proteinuria, and prednisone doses were significantly weaned off and discontinued in two patients. However, eGFR remained stable during the treatment period. TAC was well tolerated, and no adverse effects were observed.

Conclusion: TAC combined with MMF can be considered as an alternative therapeutic option for children with refractory lupus nephritis particularly those with persistent nephrotic-range proteinuria.

1. Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multiorgan involvement; the onset and clinical features of childhood SLE (cSLE) are often aggressive and require an intensive therapy [1,2]. Lupus nephritis is one of the major clinical features of SLE, occurring in up to 60% of children with SLE. It can be subclinical but occasionally present with body edema due to nephrotic-range proteinuria, hypertension, and renal impairment [3,4].

Although there is no available cure for SLE presently, several drugs are useful in controlling the disease and contributed to a favorable outcome. Children with lupus nephritis, especially diffuse proliferative and membranous glomerulonephritis, may necessitate potent immunosuppressive medications such as cyclophosphamide (CYC) or mycophenolate mofetil (MMF) and occasionally rituximab (RTX) [5,6]. However, one third of such patients might either have frequent disease flares or be resistant to the treatment with disease progression [7,8].

Tacrolimus (TAC) recently gained much attention in the treatment of adult patients with refractory lupus nephritis and children with a nephrotic syndrome [9–11]. However, the available published data in childhood lupus nephritis are limited [12–14].

* Corresponding author. Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Al-Muna Hospital, Po Box 3354, Riyadh 11211, Saudi Arabia.
E-mail address: mayouf@kfshrc.edu.sa (S.M. Al-Mayouf).

Peer review under responsibility of King Faisal Specialist Hospital & Research Centre (General Organization), Saudi Arabia.

https://doi.org/10.1016/j.ijpam.2018.08.001

© 2018 Publishing services provided by Elsevier B.V. on behalf of King Faisal Specialist Hospital & Research Centre (General Organization), Saudi Arabia. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Herein, we present three children with refractory lupus nephritis who were treated successfully with TAC. Furthermore, we reviewed all published articles on the treatment of childhood lupus nephritis with TAC.

2. Patients and methods

This is a retrospective case series of patients with refractory childhood lupus nephritis seen at King Faisal Specialist Hospital and Research Center (KFSH-RC), Riyadh. Medical records were reviewed for demographic data, clinical and laboratory parameters, histopathology and imaging findings, and response to TAC. All patients were evaluated at the time of initiation of TAC treatment, then after 3 and 6 months, and at the last follow-up visit by assessing the following response parameters: cSLE Disease Activity Index (SLEDAI), urine protein/creatinine ratio, urine sediments, serum albumin, complement (C3 and C4), anti-double-stranded DNA (dsDNA) antibody levels, and renal function assessed by estimated glomerular filtration rate (eGFR).

3. Results

Table 1 shows the clinical and laboratory findings of the three patients with refractory lupus nephritis.

3.1. First case

A 13-year-old girl was diagnosed with SLE at the age of 8 years on the basis of constitutional symptoms, malar rash, oral ulceration, and arthritis. She had leukopenia, elevated antinuclear antibody (ANA), high anti-dsDNA antibody levels, and low complement (C3 and C4) levels. Other results revealed a high erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) 39 mm/h and 22 mg/L, respectively. She also had evidence of nephritis manifested with proteinuria and nephrotic-range proteinuria. Renal biopsy proved lupus nephritis class IV. Interestingly, her mother is a known case of SLE with nephritis. She was started on prednisone (1 mg/kg/day), hydroxychloroquine (5 mg/kg/day), and azathioprine (AZA) (2 mg/kg/day). Owing to partial response, treatment was switched from AZA to MMF (600 mg/m² 12 h) was added along with hydroxychloroquine (5 mg/kg/day). Despite the treatment, she had progressive disease course with hypertension and impaired renal function. Accordingly, MMF was replaced with six doses of monthly CYC (750 mg/m²/dose) and two doses of RTX (350 mg/m²/dose). Proteinuria and hypoalbuminemia improved partially but with progressive renal impairment. Consequently, TAC (0.1 mg/kg/day) was added to her treatment regimen. Two months later, she showed good improvement in all parameters including renal function, and she was able to stop prednisone for the first time since her disease onset. During TAC treatment, she had urinary tract infection (UTI), wherein a proper oral antibiotic was administered for efficiently treating Escherichia coli.

3.2. Second case

A 13-year-old girl presented to the local hospital with features of nephrotic syndrome and was treated with prednisone 60 mg/m²/day for 4 weeks; she did not show improvement, and the renal biopsy performed proved lupus nephritis class IV. Interestingly, she did not have extra-renal manifestations of lupus, but laboratory investigations revealed positive ANA (1:160) and low C3 (0.8). Oral prednisone was continued, and MMF (600 mg/m² 12 h) was added along with hydroxychloroquine (5 mg/kg/day). Because of cardiac involvement and persistent heavy proteinuria (632 mg/mmol), treatment was switched from AZA to CYC and two doses of RTX (350 mg/m²/dose). Furthermore, she completed six doses of monthly CYC (750 mg/m²/dose), and two doses of RTX (350 mg/m²/dose), followed by MMF (600 mg/m² 12 h). She was maintained on hydroxychloroquine and variable of prednisone depending on the disease activity. Unfortunately, she had partial improvement with persistent proteinuria, and then, oral TAC at 0.1 mg/kg/day was added to MMF, hydroxychloroquine, and prednisone. Three months later, she showed significant improvement in all parameters and allowed prednisone discontinuation.

3.3. Third case

A 14-year-old boy was diagnosed at the age of 11 years with SLE on the basis of mucocutaneous manifestations, leukopenia, autoimmune hemolytic anemia diagnosed by the direct Coombs test, thrombocytopenia, positive ANA, high anti-dsDNA antibody levels, and low C3 and C4 levels with hematuria and proteinuria. Renal biopsy proved lupus nephritis class III. He was treated with prednisone (2 mg/kg/day), hydroxychloroquine (5 mg/kg/day), and AZA (2 mg/kg/day). Owing to partial response, treatment was switched from AZA to MMF (600 mg/m² 12 h).

Table 1
Baseline clinical and laboratory findings of three patients with refractory lupus nephritis.

| Case I | Case II | Case III |
|--------|---------|----------|
| Age (Years)/Gender | 13/Female | 12/Female | 14/Male |
| Age at onset (SLE) (Years) | 8 | 11 | 8 |
| Lupus nephritis (SSN/RPS) | IV | IV | IV/V |
| Extra-renal | Mucocutaneous | Hematological | Mucocutaneous |
| | Musculoskeletal | Musculoskeletal | |
| | Hematological | Hematological | |
| Urine Pr/Cr ratio (mg/mmol) | 424 | 120 | 629 |
| Urine sediments | 5 RBC, 5 WBC+; Hyaline cast | Negative | >50 RBC, 5 WBC+; Granular cast |
| C3 g/L (0.9–1.8) | 0.79 | 1 | 0.8 |
| C4 g/L (0.1–0.4) | 0.3 | 0.4 | 0.1 |
| eGFR min/ml/1.73 m² | 157 | 43 | 162 |
| Serum albumin mg/L | 30 | 34 | 27 |
| Anti-dsDNA antibody (>=200) | 1280 | Negative | 456 |
| Daily Steroid dose (mg) | 10 | 5 | 5 |
| Previous medications | MMF, RTX, CYC, IVIG | MMF, RTX, CYC, IVIG | MMF, RTX, CYC, IVIG |
| SLEDAI | 9 | 4 | 14 |

C3, complement 3; C4, Complement 4; dsDNA, double-stranded DNA; ANA, antinuclear antibody; AAZ, azathioprine; CYC, cyclophosphamide; RTX, rituximab; MMF, mycophenolate mofetil; IVIG, intravenous immunoglobulin; SLEDAI, systemic lupus erythematosus disease activity index.

* Urine protein/creatinine ratio (<30 mg/mmol).
Two years later, he presented with nephritic/nephrotic manifestations; hence, renal biopsy was repeated and showed lupus nephritis class IV and V. Accordingly, MMF was replaced by CYC (750 mg/m²/dose), for six doses monthly, and then another six doses for every 3 months; then, he was maintained on MMF but showed partial response. He required two cycles of RTX (350 mg/kg/day) was added to MMF, and he showed good improvement.

3.4. Clinical assessment

All patients showed improvement in response parameters, namely, SLEDAI, serum albumin, and urine protein/creatinine ratio (Fig. 1). However, eGFR remained stable during the treatment period. Prednisone was weaned gradually and was stopped in two patients. TAC was well tolerated, and no significant adverse effects were observed except in one patient who had simple UTI. Table 2 summarizes the results of response to TAC during the follow-up period.

4. Discussion

Management of lupus nephritis remains a great challenge particularly in children with active nephritis and persistent heavy proteinuria [14]. CYC and MMF are still considered as the induction therapy for proliferative lupus nephritis, but MMF is considered as a suitable maintenance therapy. Additionally, MMF might be the preferred induction and maintenance therapy for membranous lupus nephritis [15]. By this approach, the disease relapse rate reduced and the outcome improved significantly. Despite that, renal flare can occur in up to 50% during the maintenance treatment. Thus, in active nephritis or persistent proteinuria, immunosuppressive drugs can be switched to another agent within 3–6 months of treatment [15,16]. Although, evidence is limited, combination of RTX and MMF or CYC might provide efficacious therapeutic effect for refractory cases of SLE including nephritis. However, it was associated with a high rate of infection [17,18].

TAC recently showed encouraging results suggesting its efficacy in adult patients with refractory lupus nephritis, especially in reducing proteinuria [9,19].

The available data in childhood lupus nephritis are limited. Almost all published data came from one institution. Tanaka et al. followed a cohort of children with lupus nephritis treated with TAC; the results suggest that TAC is beneficial with low cytotoxicity [12,13]. A new treatment option in patients who were refractory to the standard treatment is the multitarget treatment such as a combination of TAC and MMF [20,21].

Our patients had refractory lupus nephritis with persistent heavy proteinuria showing partial response to sequential CYC, MMF, and RTX treatment. Fortunately, combined treatment of TAC and MMF showed beneficial therapeutic effect within 3 months of treatment. This regimen led to complete remission of proteinuria and constant improvement in eGFR. Furthermore, prednisone was discontinued in two patients. Interestingly, none of them had relapses after initiation of this regimen until the last follow-up visit.

Evidence is limited for the use of TAC for treating childhood lupus nephritis. However, if a patient with cSLE with heavy proteinuria resists the standard induction treatment within 6 months, it is worth considering TAC as an alternative therapeutic option. This work had several limitations; it included a small number of patients. Moreover, it is an open uncontrolled study with patients treated in an unblinded manner.

Conflicts of interest

The authors have nothing to disclose related to this work. This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

[1] Morgan T, Watson L, McCann L, Beresford M. Children and adolescents with SLE: not just little adults. Lupus 2013;22:1309–19.
[2] Kamphuis S, Silverman E. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 2010;6:38–46.
[3] Wu J, Yeh K, Huang J. Early predictors of outcomes in pediatric lupus nephritis: focus on proliferative lesions. Semin Arthritis Rheum 2014;43:513–20.
[4] Sato V, Marques D, Goldenstein P, Carmo L, Jorge L, Titan S, et al. Lupus nephritis is more severe in children and adolescents than in older adults. Lupus 2012;21:978–83.
[5] Bosepathar A, Radhakrishna S, Greenbaum I, Yen E, Okamura D, Cooper J, et al. Approach to membranous lupus nephritis: a survey of pediatric nephrologists and pediatric rheumatologists. J Rheumatol 2017;44:1619–23.
[6] Hogan J, Godron A, Baudouin V, Kwon T, Harambalt J, Deschenes G, et al. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis. Pediatr Nephrol 2018;33:111–6.
[7] Groot N, de Graeff N, Marks S, Brogan P, Avein T, Bader-Meunier B, Dolezaova P, et al. European evidence-based recommendation for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative.
[8] Chen Y, Korbet S, Katz R, Schwartz M, Lewis E. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008;3:46–53.
[9] Hannah J, Casian A, D'Cruz D. Tacrolimus use in lupus nephritis: a systematic review and meta-analysis. Autoimmun Rev 2016;15:93–101.
[10] Choi C, Won S, Bae S. Outcome of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. Lupus 2018;27:1007–11.
[11] Chatzidimitriou A, Trachana M, Prasidou-Gerts P. The role of tacrolimus in the step-up induction therapy of refractory childhood-onset lupus nephritis. Hippokratia 2015;19:378.
[12] Tanaka H, Oki E, Tsuruga K, Nonaka K, Suzuki K, Ito E. Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: an open-label pilot study. Lupus 2007;16:896–900.
[13] Tanaka H, Watanabe S, Aizawa-Yashiro T, Oki E, Kumagai N, Tsuruga K, et al. Long-Term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice. Nephron Clin Pract 2013;123:165–73.
[14] Tanaka H, Joh K, Imaizumi T. Treatment of pediatric-onset lupus nephritis: a proposal of optimal therapy. Clin Exp Nephrol 2017;2:755–63.
[15] Groot N, de Graeff N, Marks S, Brogan P, Avcin T, Bader-Meunier B, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis 2017;76:1965–73.
[16] Elmougy A, Sarhan A, Hammad A, El-Refaey A, Zedan M, Eid R, et al. Lupus nephritis in Egyptian children: a 16-year experience. J Nephrol 2015;28:557–62.
[17] Al'eed A, Alsonul A, Al-Mayouf SM. Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus. Rheumatol Int 2014;34:529–33.
[18] Hogan J, Godron A, Baudouin V, Kwon T, Harambat J, Deschenes G, et al. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis. Pediatr Nephrol 2018;33:111–6.
[19] Yap D, Ma M, Mok M, Kwan L, Chan G, Chan T, et al. Long-term data on tacrolimus treatment in lupus nephritis. Rheumatology 2014;53:2232–7.
[20] Tanaka H, Aizawa T, Watanabe S, Oki E, Tsuruga K, Imaizumi T. Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis. Lupus 2014;23:8130–818.
[21] Choi C, Won S, Bae S. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. Lupus 2018;27:1007–11.